Aslan Bullish On Once-Monthly Dosing For Eblasakimab In Atopic Dermatitis

 
• By Jessica Merrill
  
raise the bar
Aslan says it raised the efficacy bar in AD; investors aren't as sure • Source: Shutterstock

More from Clinical Trials

More from R&D